Last week Johnson & Johnson disclosed in its 10Q filing with the Securities & Exchange Commission that its subsidiary, Janssen Pharmaceuticals, Inc. (JPI) was served with a Civil Investigative Demand (CID) from the U.S. Attorney’s Office for the Southern District of New York. The March 2016 CID is seeking information related to JPI’s contractual relationships with pharmacy benefit managers (PBM) over the period from January 1, 2006 to the present with regard to unspecified J